WP
FHTX icon

Woodline Partners’s Foghorn Therapeutics FHTX Stock Holding History

Woodline Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$986K Buy
202,145
+21,812
+12% +$96.8K ﹤0.01% 917
2026
Q1 		$862K Buy
180,333
+158,810
+738% +$872K ﹤0.01% 903
2025
Q4 		$116K Sell
21,523
-87,073
-80% -$395K ﹤0.01% 1008
2025
Q3 		$531K Buy
+108,596
New +$576K ﹤0.01% 833
2021
Q1 		– Sell
-103,040
Closed -$2.09M – 444
2020
Q4 		$2.09M Buy
+103,040
New +$1.97M 0.06% 194

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Woodline Partners's FHTX Position: Q2 2026 in Review

Woodline Partners increased its Foghorn Therapeutics (FHTX) stake by 12% in Q2 2026, buying an estimated $96.8K and bringing the position to 202,145 shares worth $986K. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Woodline Partners first reported a position in FHTX in Q4 2020 and has held it in 5 quarters since. The position peaked at $2.09M in Q4 2020. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Woodline Partners held 202,145 shares of Foghorn Therapeutics worth $986K as of Q2 2026.
  • Woodline Partners bought 21,812 Foghorn Therapeutics shares in Q2 2026, an estimated $96.8K.
  • Foghorn Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #917 holding.
  • Woodline Partners first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Woodline Partners's Foghorn Therapeutics position peaked at $2.09M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.